Capvizr
THE DEAL, AT A GLANCE

SereNeuro

From the announcement
01
MoleculesDrug research
Medicine development
What it doesSereNeuro Therapeutics is a preclinical biotech developing non-opioid therapies for chronic pain, specifically targeting chronic osteoarthritis joint pain (SN101) and…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02What happenedSereNeuro raised Pre-Seed, announced 2026-10-05From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03Why it mattersSereNeuro's $0M Pre-Seed positions a preclinical non-opioid pain-therapy biotech inside a crowded Unclassified tape, where 905 other funding rounds totaled $675254M in…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

SereNeuro · Financing Record

Explore source-linked visual explanations for SereNeuro. Unsupported claims are withheld while source review continues.

Record 13423 · Recorded date: 2026-10-05

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime